Cost-effectiveness of hepatitis B vaccination using HEPLISAV in selected adult populations compared to Engerix-B vaccine
Kuan RK, Janssen R, Heyward W, Bennett S, Nordyke R
 
 
Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.
Bibliographic details
Kuan RK, Janssen R, Heyward W, Bennett S, Nordyke R. Cost-effectiveness of hepatitis B vaccination using HEPLISAV in selected adult populations compared to Engerix-B vaccine. Vaccine 2013; 31(37): 4024-4032
PubMedID
23707166
DOI
10.1016/j.vaccine.2013.05.014
Indexing Status
Subject indexing assigned by NLM
MeSH
Adolescent; Adult; Aged; Cost-Benefit Analysis; Diabetes Mellitus /economics /virology; Health Personnel; Hepatitis B /prevention & Hepatitis B Vaccines /administration & Humans; Kidney Failure, Chronic /economics /virology; Markov Chains; Middle Aged; Models, Economic; Models, Theoretical; Probability; Renal Insufficiency, Chronic /economics /virology; Young Adult; control; dosage /economics /therapeutic use
AccessionNumber
22013022412
Date bibliographic record published
21/06/2013
 
NHS Economic Evaluation Database (NHS EED)
Produced by the Centre for Reviews and Dissemination
Copyright © 2026 University of York
 
Homepage
Options
Print
PDF
 
PubMed record
Original research
 
Share
 

Message for NHS EED database users